With a $1.8 billion purchase with CinCor, AstraZeneca grows its heart and kidney businesses.

9 January (Reuters) AstraZeneca (AZN.L) declared on Monday that it has reached an agreement to acquire American drug-development company CinCor Pharma Inc (CINC.O) for up to $1.8 billion in order to expand its supply of heart and kidney medications.

The experimental medication baxdrostat, which is being developed by CinCor to treat illnesses like high blood pressure and chronic renal disease, is at the heart of the agreement.

Read More

AstraZeneca agreed to $760 million deal with the Swiss firm Neurimmune for an antibody drug

In a deal worth up to $760 million, AstraZeneca Plc announced on Tuesday that it had reached an agreement with Swiss biotechnology firm Neurimmune to develop an antibody-based therapy for a rare, underdiagnosed condition that can lead to heart failure. Alexion and Neurimmune from AstraZeneca’s rare diseases unit will collaborate to evaluate NI006, a monoclonal…

Read More

Enjoy this blog? Please spread the word :)

Follow by Email